Prognostic significance of preoperative serum CYFRA 21-1 in patients with upper urinary tract urothelial carcinoma

International Journal of Urology

Volumn 18, Issue 1, 2011, Pages 43-47

  Suyama, Taisuke ^a   Nakajima, Koichi ^a   Kanbe, Shigeki ^b   Tanaka, Norie ^b   Hara, Hiroshi ^b   Ishii, Nobuhisa ^b  

^a TOHO UNIVERSITY OHASHI MEDICAL CENTER   (Japan)

^b TOHO UNIVERSITY OMORI MEDICAL CENTER   (Japan)

Author keywords

Carcinoma; CYFRA 21 1; Predictor; Pretreatment; Upper urinary tract

Indexed keywords

C REACTIVE PROTEIN; CYTOKERATIN 19 FRAGMENT; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CORRELATION ANALYSIS; DISTANT METASTASIS; FEMALE; FOLLOW UP; HUMAN; MALE; NEPHROURETERECTOMY; OVERALL SURVIVAL; PREDICTOR VARIABLE; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; REFERENCE VALUE; RETROSPECTIVE STUDY; SURVIVAL RATE; TRANSITIONAL CELL CARCINOMA; URINARY TRACT CARCINOMA; URINE CYTOLOGY;

AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; CARCINOMA; FEMALE; HUMANS; JAPAN; KERATIN-19; MALE; MIDDLE AGED; PREOPERATIVE CARE; PROGNOSIS; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL; UROLOGIC NEOPLASMS;

EID: 78650642084     PISSN: 09198172     EISSN: 14422042     Source Type: Journal    
DOI: 10.1111/j.1442-2042.2010.02671.x     Document Type: Article

References (18)

1. Moll R, Franke W, Schiller D, Geiger B, Krepler R. The catalog of human cytokeratins: patterns of expression in normal epithelia, tumors and cultured cells. Cell 1982; 31: 11-24.
2. Pariente J, Bordenave L, Jacob F et al. Analytical and prospective evaluation of urinary cytokeratin 19 fragment in bladder cancer. J. Urol. 2000; 163: 1116-19.
3. Pujol J, Simony J, Laurent J et al. Phenotypic heterogeneity studied by immunohistochemistry and aneuploidy in non-small cell lung cancers. Cancer Res. 1989; 49: 2797-802.
4. Sánchez-Carbayo M, Espasa A, Chinchilla V et al. New electrochemiluminescent immunoassay for the determination of CYFRA 21-1: analytical evaluation and clinical diagnostic performance in urine samples of patients with bladder cancer. Clin. Chem. 1999; 45: 1944-53.
5. Pariente J, Bordenave L, Michel P, Latapie M, Ducassou D, Le Guillou M. Initial evaluation of CYFRA 21-1 diagnostic performances as a urinary marker in bladder transitional cell carcinoma. J. Urol. 1997; 158: 338-41.
6. Senga Y, Kimura G, Hattori T, Yoshida K. Clinical evaluation of soluble cytokeratin 19 fragments (CYFRA 21-1) in serum and urine of patients with bladder cancer. Urology 1996; 48: 703-10.
7. Reedy E, Colombo-Burke K, Resau J. Discrimination of cell types in primary transitional cell carcinoma by monoclonal anti-cytokeratin antibodies. Pathobiology 1990; 58: 304-11.
8. Carbin B, Collins V, Ekman P. Tissue polypeptide antigen (TPA), some cytokeratins and epithelial membrane antigen (EMA) in normal, inflamed and malignant urothelium. Urol. Res. 1987; 15: 191-4.
9. Stieber P, Hasholzner U, Bodenmuller H et al. CYFRA 21-1. A new marker in lung cancer. Cancer 1993; 72: 707-13.
10. Andreadis C, Touloupidis S, Galaktidou G, Kortsaris A, Boutis A, Mouratidou D. Serum CYFRA 21-1 in patients with invasive bladder cancer and its relevance as a tumor marker during chemotherapy. J. Urol. 2005; 174: 1771-5; discussion 1775-6.
11. Pectasides D, Bafaloucos D, Antoniou F et al. TPA, TATI, CEA, AFP, beta-HCG, PSA, SCC, and CA 19-9 for monitoring transitional cell carcinoma of the bladder. Am. J. Clin. Oncol. 1996; 19: 271-7.
12. Mady E. Cytokeratins as serum markers in egyptian bladder cancer. A comparison of CYFRA 21-1, TPA and TPS. Int. J. Biol. Markers 2001; 16: 130-5.
13. Saito K, Kawakami S, Fujii Y, Sakura M, Masuda H, Kihara K. Lymphovascular invasion is independently associated with poor prognosis in patients with localized upper urinary tract urothelial carcinoma treated surgically. J. Urol. 2007; 178: 2291-6; discussion 2296.
14. Nisman B, Barak V, Shapiro A, Golijanin D, Peretz T, Pode D. Evaluation of urine CYFRA 21-1 for the detection of primary and recurrent bladder carcinoma. Cancer 2002; 94: 2914-22.
15. Fernandez-Gomez J, Rodríguez-Martínez J, Barmadah S et al. Urinary CYFRA 21.1 is not a useful marker for the detection of recurrences in the follow-up of superficial bladder cancer. Eur. Urol. 2007; 51: 1267-74.
16. Saito K, Kawakami S, Ohtsuka Y et al. The impact of preoperative serum C-reactive protein on the prognosis of patients with upper urinary tract urothelial carcinoma treated surgically. BJU Int. 2007; 100: 269-73.
17. Pujol JL, Grenier J, Daures JP, Daver A, Pujol H, Michel FB. Serum fragment of cytokeratin subunit 19 measured by CYFRA 21-1 immunoradiometric assay as a marker of lung cancer. Cancer Res. 1993; 53: 61-6.
18. Stieber P, Dienemann H, Hasholzner U et al. Comparison of CYFRA 21-1, TPA and TPS in lung cancer, urinary bladder cancer and benign diseases. Int. J. Biol. Markers 1994; 9: 82-8.